

© 2023 Tu Y. Published by Elsevier.

Acknowledgment

Conflict of Interest

References

1. Baell JB, Holloway GA (2010) New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. *J Med Chem* 2719-2740.
2. Bajorath J, Peltason L, Wawer M (2009) Navigating structure-activity landscapes. *Drug Discov Today* 14 (13-14): 698-705.
3. Berry M, Fielding BC, Gamielien J (2015) Potential broad Spectrum inhibitors of the coronavirus 3CLpro a virtual screening and structure-based drug design. *studyViruses* 7 (12): 6642-6660.
4. Capuzzi SJ, Muratov EN, TropshaPhantomA (2017) Problems with the Utility of Alerts for Pan-Assay INterference Compound. *J Chem Inf Model* 57 (3): 417-427.
5. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A (2020) A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. *J Crit Care* 57 (3): 417-427.
6. Dong E, Du EL, Gardner L (2020) An interactive web-based dashboard to track COVID-19 in real time *Lancet. Infect Dis* 7 (12): 6642-6660.
7. Fan HH, Wang LQ (2020) Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus. *Model Chin Med J*
8. Gao J, Tian Z, Yan X (2020) Breakthrough Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci Trends* 14 (1): 72-73.
9. Flexner C (1998) HIV-protease inhibitors *N Engl J Med* 338:1281-1292.
10. Ghosh AK, Osswald HL (2016) Prato Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV/AIDS. *J Med Chem* 59 (11): 5172-5208.